Research Analysts Set Expectations for TNGX FY2025 Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Equities researchers at Wedbush lifted their FY2025 earnings per share (EPS) estimates for shares of Tango Therapeutics in a research note issued on Thursday, October 23rd. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share of ($1.35) for the year, up from their previous estimate of ($1.38). The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share. Wedbush also issued estimates for Tango Therapeutics’ Q4 2025 earnings at ($0.29) EPS, Q1 2026 earnings at ($0.29) EPS, Q2 2026 earnings at ($0.30) EPS, Q3 2026 earnings at ($0.31) EPS, Q4 2026 earnings at ($0.32) EPS, FY2026 earnings at ($1.22) EPS, FY2027 earnings at ($1.16) EPS, FY2028 earnings at ($0.29) EPS and FY2029 earnings at $0.38 EPS.

TNGX has been the topic of a number of other research reports. Guggenheim lifted their price objective on Tango Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday. Piper Sandler started coverage on Tango Therapeutics in a research note on Monday, August 18th. They issued an “overweight” rating and a $11.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tango Therapeutics in a research note on Friday. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Tango Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $11.00.

Tango Therapeutics Price Performance

NASDAQ:TNGX opened at $7.49 on Monday. Tango Therapeutics has a 1 year low of $1.03 and a 1 year high of $9.70. The stock’s 50 day simple moving average is $7.51 and its two-hundred day simple moving average is $5.21. The company has a market cap of $833.34 million, a price-to-earnings ratio of -5.63 and a beta of 1.67.

Tango Therapeutics (NASDAQ:TNGX) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.35) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.35). Tango Therapeutics had a negative return on equity of 79.72% and a negative net margin of 599.11%.The business had revenue of $3.18 million for the quarter, compared to the consensus estimate of $6.41 million.

Insider Buying and Selling at Tango Therapeutics

In other news, major shareholder Rock Ventures Iv L.P. Third sold 1,100,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $7.01, for a total transaction of $7,711,000.00. Following the transaction, the insider owned 15,759,075 shares of the company’s stock, valued at approximately $110,471,115.75. The trade was a 6.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders sold 2,995,100 shares of company stock worth $21,504,700. Insiders own 7.50% of the company’s stock.

Institutional Trading of Tango Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC lifted its position in shares of Tango Therapeutics by 96.6% during the first quarter. Acadian Asset Management LLC now owns 973,309 shares of the company’s stock worth $1,327,000 after purchasing an additional 478,203 shares during the last quarter. Russell Investments Group Ltd. lifted its position in shares of Tango Therapeutics by 2,376.2% during the first quarter. Russell Investments Group Ltd. now owns 51,183 shares of the company’s stock worth $73,000 after purchasing an additional 49,116 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of Tango Therapeutics by 42.6% during the first quarter. Jacobs Levy Equity Management Inc. now owns 737,955 shares of the company’s stock worth $1,011,000 after purchasing an additional 220,529 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Tango Therapeutics by 9.9% during the first quarter. Bank of New York Mellon Corp now owns 113,233 shares of the company’s stock worth $155,000 after purchasing an additional 10,213 shares during the last quarter. Finally, Nuveen LLC bought a new stake in shares of Tango Therapeutics during the first quarter worth $277,000. 78.99% of the stock is currently owned by institutional investors.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.